Screening for prevention and early diagnosis of cancer.

Скрининг для профилактики и ранней диагностики рака
Jane Wardle, Kathryn A. Robb, Sally W. Vernon, Jo Waller
2015-02-01

cancer screeningearly cancer detectionoverdiagnosisrisk-stratified screeningscreening uptake
The poor outcomes for cancers diagnosed at an advanced stage have been the driver behind research into techniques to detect disease before symptoms are manifest. For cervical and colorectal cancer, detection and treatment of "precancers" can prevent the development of cancer, a form of primary prevention. For other cancers-breast, prostate, lung, and ovarian-screening is a form of secondary prevention, aiming to improve outcomes through earlier diagnosis. International and national expert organizations regularly assess the balance of benefits and harms of screening technologies, issuing clinical guidelines for population-wide implementation. Psychological research has made important contributions to this process, assessing the psychological costs and benefits of possible screening outcomes (e.g., the impact of false positive results) and public tolerance of overdiagnosis. Cervical, colorectal, and breast screening are currently recommended, and prostate, lung, and ovarian screening are under active review. Once technologies and guidelines are in place, delivery of screening is implemented according to the health care system of the country, with invitation systems and provider recommendations playing a key role. Behavioral scientists can then investigate how individuals make screening decisions, assessing the impact of knowledge, perceived cancer risk, worry, and normative beliefs about screening, and this information can be used to develop strategies to promote screening uptake. This article describes current cancer screening options, discusses behavioral research designed to reduce underscreening and minimize inequalities, and considers the issues that are being raised by informed decision making and the development of risk-stratified approaches to screening.
1
Breast, prostate, lung, and ovarian screening primarily aim to improve outcomes through earlier cancer diagnosis rather than preventing cancer onset.
2
Cervical, colorectal, and breast cancer screening are recommended, whereas prostate, lung, and ovarian screening remain under active review.
3
Expert organizations weigh screening benefits against harms, including false-positive psychological impacts and public tolerance of overdiagnosis, when developing guidelines.
4
Informed decision making and risk-stratified screening are emerging issues shaping the future design and delivery of cancer screening.
5
Invitation systems, provider recommendations, perceived cancer risk, worry, knowledge, and normative beliefs influence screening uptake and may help address underscreening and inequalities.
6
Screening for cervical and colorectal cancer can prevent cancer by detecting and treating precancerous lesions before malignancy develops.

Cancer screening for cervical, colorectal, breast, prostate, lung, and ovarian cancers

Screening-based prevention and early diagnosis, including the psychological benefits and harms, screening decision-making, uptake, underscreening, inequalities, and risk stratification

Publication Details
Publication Date
2015-02-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Jane Wardle
Kathryn A. Robb
Sally W. Vernon
Jo Waller
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%